Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $27.00 Price Target at HC Wainwright

Enanta Pharmaceuticals (NASDAQ:ENTA) had its price target decreased by stock analysts at HC Wainwright from $28.00 to $27.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 105.48% from the company’s previous close.

Several other research analysts have also issued reports on the company. StockNews.com lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, April 6th. JPMorgan Chase & Co. cut their price target on Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating on the stock in a report on Thursday, February 8th. Finally, JMP Securities dropped their target price on Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating on the stock in a report on Tuesday. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $19.00.

Enanta Pharmaceuticals Trading Down 10.0 %

NASDAQ ENTA traded down $1.46 during trading hours on Tuesday, hitting $13.14. 195,364 shares of the company’s stock were exchanged, compared to its average volume of 244,088. The stock has a 50-day simple moving average of $14.93 and a 200 day simple moving average of $12.05. Enanta Pharmaceuticals has a 1-year low of $8.08 and a 1-year high of $36.04. The firm has a market cap of $278.04 million, a price-to-earnings ratio of -2.01 and a beta of 0.54.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.18) by ($0.40). Enanta Pharmaceuticals had a negative return on equity of 60.38% and a negative net margin of 187.77%. The business had revenue of $18.00 million for the quarter, compared to analyst estimates of $22.74 million. On average, sell-side analysts anticipate that Enanta Pharmaceuticals will post -4.9 earnings per share for the current fiscal year.

Institutional Trading of Enanta Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Nisa Investment Advisors LLC increased its position in shares of Enanta Pharmaceuticals by 417.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 2,281 shares during the last quarter. Strs Ohio increased its position in Enanta Pharmaceuticals by 20.6% in the fourth quarter. Strs Ohio now owns 18,700 shares of the biotechnology company’s stock worth $175,000 after buying an additional 3,200 shares during the last quarter. Clearstead Advisors LLC purchased a new stake in Enanta Pharmaceuticals in the third quarter worth $57,000. Quantbot Technologies LP increased its position in Enanta Pharmaceuticals by 2,300.0% in the third quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock worth $80,000 after buying an additional 6,900 shares during the last quarter. Finally, Sherbrooke Park Advisers LLC purchased a new stake in Enanta Pharmaceuticals in the third quarter worth $113,000. 94.99% of the stock is owned by hedge funds and other institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.